BioSyngen

Private

SingaporeHealthcare & Life Scienceshttps://biosyngen.com

Last Round

Early Funding

Oct 20, 2021

Total Funding Raised

$43.5M

Company Overview

BioSyngen is a biotechnology company that develops first-in-class cell therapies, including CAR-T, TCR-T, and TILs, to treat solid tumors and other cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cell and gene therapyCAR-T therapycancer immunotherapyT-cell therapyCGTsolid tumor treatmentTCR-T therapyTIL therapyTumor-Infiltrating Lymphocytesautologous cell therapyGMP manufacturingGood Manufacturing Practiceclinical-stage biotechEBV-positive cancersnasopharyngeal carcinomaautomated cell manufacturingantigen discoveryOrphan Drug Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioSyngen Comparables

Compare BioSyngen with similar companies based on industry and business-model similarity.

BioSyngen comparables — related companies by embedding similarity
Company	Similarity	Market Cap
TCRCure Biopharma	87%
Lion TCR	84%
SCG Cell Therapy	84%

View all Comparables

BioSyngen Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Oct 20, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Hao Shen

President & CEO

Executive Team

BioSyngen Investors

Notable investors and investment history

BioSyngen investors
Investor	Rounds
Science City (Guangzhou) Investment Group Co., Ltd.	Early Funding

View all Investors

BioSyngen Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

BioSyngen Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersSingapore

Employee Range15

Year Founded2016

Last FundingOct 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?